NVCR NovoCure Limited
USHealthcareAs of 2026-07-10 16:00
Why NVCR matters now
NovoCure Limited (NVCR) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.30 with -5.73% on the session and $1.89B in market capitalization; recent performance reads 1-month -16.05% and YTD +10.44%.
The latest financial table shown here is Q1 2026, with revenue of $174.1M, net income of $-71.1M, and EPS of $-0.62. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.9%.
The latest indexable market news headline is "NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $33.00; recent insider activity includes Leonard Frank X filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.93
P/S
2.45
EV/EBITDA
-11.53
DCF Value
$-29.61
FCF Yield
-2.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.2%
Operating Margin
-27.2%
Net Margin
-25.7%
ROE
-50.8%
ROA
-22.0%
ROIC
-31.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $174.1M | $-71.1M | $-0.62 |
| Q4 2025 | $174.3M | $-24.5M | $-0.22 |
| FY 2025 | $655.4M | $-136.2M | $-1.22 |
| Q3 2025 | $167.2M | $-37.3M | $-0.33 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$33.00
Target (Median)
$33.00
Target Range
$20.00 - $46.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.92
NovoCure Limited operates as an oncology enterprise specializing in the development, manufacturing, and global commercialization of its proprietary Tumor Treating Fields (TTFields) technology. These innovative devices are engineered to treat solid tumor cancers, with the company's market presence spanning the United States, Europe, the Middle East, Africa, Japan, and Greater China. The company's commercialized offerings include Optune, which is indicated for glioblastoma, and Optune Lua, approved for use in malignant pleural mesothelioma. Beyond these established treatments, NovoCure actively conducts, or has completed, clinical research into the potential applications of TTFields for a broader spectrum of cancers. These investigational areas encompass brain metastases, gastric cancer, further studies in glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Founded in 2000, NovoCure Limited is headquartered in Saint Helier, Jersey.